Gestagens in the treatment of endometriosis

• DOI: 10.14341/probl8742
• Publication Date: 2018-05-06T01:30:31Z
• Authors: Tatiana A. Fedotc...; Nikolai L. Shiman...
• Keywords: Pathogenesis

Endometriosis occurs in 10% of females reproductive age and ranks third among gynecological diseases, being one the causes infertility. The success endometriosis treatment depends on individually selected therapy based molecular-genetic characterization patient endometrial tissue. review addresses mechanisms development role gestagens pathogenesis this disease. We describe genetic epigenetic development, which lead to resistance endogenous progesterone, a key link endometriosis. Because gestagen monotherapy is considered as first-line treatment, we analyze properties that underlie indications for their use In particular, should have high gestagenic activity an antiproliferative effect target cells. An original domestic drug, oral Gestobutanoil 17a-acetoxy-3b-butanoyloxy-6-methyl-pregna-4,6-dien-20-one (AMP-17), promising clinical use. AMP-17 Clauberg-McPhail test 102-fold higher than progesterone. has pronounced estrogen-dependent targets, such breast cancer cells, cervical etc.